379 related articles for article (PubMed ID: 9734140)
21. Disseminated intravascular coagulation: What's new?
Levi M
Crit Care Clin; 2005 Jul; 21(3):449-67. PubMed ID: 15992667
[TBL] [Abstract][Full Text] [Related]
22. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
[TBL] [Abstract][Full Text] [Related]
23. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
Carpenter SL; Mathew P
Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
[TBL] [Abstract][Full Text] [Related]
24. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
Prins MH; Hirsh J
Arch Intern Med; 1991 Sep; 151(9):1721-31. PubMed ID: 1888237
[TBL] [Abstract][Full Text] [Related]
25. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Li F; Zhang G; Zhao W
Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
[TBL] [Abstract][Full Text] [Related]
26. Anabolic steroids and fibrinolysis.
Lowe GD
Wien Med Wochenschr; 1993; 143(14-15):383-5. PubMed ID: 8256452
[TBL] [Abstract][Full Text] [Related]
27. [Coagulation tests in septic surgical patients].
Oberhofer D; Kucisec-Tepes N; Skok J; Vucić N; Cala K
Acta Med Croatica; 2004; 58(5):389-94. PubMed ID: 15756805
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the pro-thrombotic state in CAPD patients.
Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
[TBL] [Abstract][Full Text] [Related]
29. [The TAFI system. The new role of fibrinolysis].
Dempfle CE
Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
[TBL] [Abstract][Full Text] [Related]
30. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
31. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
Gando S; Hayakawa M; Sawamura A; Hoshino H; Oshiro A; Kubota N; Jesmin S
Thromb Res; 2007; 121(1):67-73. PubMed ID: 17397908
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
33. [Actilyse: biological aspects].
Samama M; Cormier B; Conard J
Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():51-7. PubMed ID: 3142427
[TBL] [Abstract][Full Text] [Related]
34. [Natural inhibitors of fibrinolysis and thrombohemorrhagic phenomena].
Moriau M
Pathol Eur; 1969; 4():Suppl 1:9-286. PubMed ID: 4244510
[No Abstract] [Full Text] [Related]
35. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
36. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Keller TT; van der Sluijs KF; de Kruif MD; Gerdes VE; Meijers JC; Florquin S; van der Poll T; van Gorp EC; Brandjes DP; Büller HR; Levi M
Circ Res; 2006 Nov; 99(11):1261-9. PubMed ID: 17068293
[TBL] [Abstract][Full Text] [Related]
37. Coagulation abnormalities in malignancy: a review.
Bick RL
Semin Thromb Hemost; 1992; 18(4):353-72. PubMed ID: 1470924
[TBL] [Abstract][Full Text] [Related]
38. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
39. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Kostka B; Para J; Sikora J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
[TBL] [Abstract][Full Text] [Related]
40. Role of fibrinolysis in obesity and thrombosis.
Lijnen HR
Thromb Res; 2009; 123 Suppl 4():S46-9. PubMed ID: 19303504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
